"These things don't get immediately disentangled, " says Church, who worked in the medical biotech business as a researcher in the early days of Biogen, now part of Biogen Idec, before coming to Harvard.
"These things don't get immediately disentangled, " says Church, who worked in the medical biotech business as a researcher in the early days of Biogen, now part of Biogen Idec (nasdaq: BIIB - news - people ), before coming to Harvard.
The first is one that I would advise caution in exploring: medical and biotech stocks.
FORBES: Book Review: The Little Book Of Big Profits From Small Stocks
Sarepta, the developer of a new muscular dystrophy drug with extremely promising results, saw its shares gain more than any other medical stock in my monthly scan of biotech, pharma, and medical device stocks.
FORBES: Sarepta Outperformed Biotechs In August Due To Muscular Dystrophy Drug
Sadly, August was mainly a bust when it came to biotech and medical stocks.
The state is also very aggressive in attracting biotech and medical device companies.
Paradoxically, China is actively developing a medical sector, including biotech, that is creating a number of high-performing companies and personal fortunes.
An astonishing number of ideas and scientists, as well as most of San Diego's 499 biotech and medical device companies, have roots in UCSD or places like Scripps and Salk.
Across the Medicon Valley centres, some 40, 000 people are employed in more than 100 biotech companies and 200 medical research ventures.
The jewel in the crown of the burgeoning biotech industry is the Oklahoma Medical Research Foundation, which is developing into a research institute of national importance, especially in the field of immunology.
Today, when you read about trends in venture capital investment, it would seem that you should have a funeral dirge playing in the background: investments are down 21% in software, 32% in biotech and 27% in medical devices.
Thomas Schaible, vice president of medical affairs at the company's Centocor biotech division, says he's not worried about reproducing Remicade's results.
John McCamant, editor of the Medical Technology Stock Letter, urges his readers not to bail on biotech.
应用推荐